ERBB2 and breast cancer: To assess whether the differential expression of CD36 in EMT-like vs. MET-like neoplastic stem-like cell subsets can be used to predict susceptibility to trastuzumab, we tested FFPE diagnostic biopsies obtained from HER2 + BC patients who received neoadjuvant trastuzumab plus chemotherapy (n = 36) by multiplex immunostaining (Table 2).